Members of the COW Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program. Listed below are the COW Board members.
Board Co-Chairs
Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Dr Saag reported no relevant financial relationships with ineligible companies. (Updated March 20, 2025)
Marshall J. Glesby, MD, PhD
Professor of Medicine and Healthcare Policy and Research
Weill Cornell Medicine
New York, New York
Dr Glesby reported no relevant financial relationships with ineligible companies. (Updated March 20, 2025)
Board Members
Roger J. Bedimo, MD, MS
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas
Dr Bedimo reported receiving research grants awarded to his institution from Merck & Co, Inc; and serving on the scientific advisory boards for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, Shionogi, and Janssen Pharmaceuticals. (Updated February 12, 2025)
Kara W. Chew, MD, MS
Assistant Professor of Medicine
University of California Los Angeles David Geffen School of Medicine
Los Angeles, California
Dr Chew reported consulting or advising fees from Pardes Biosciences; research grants to their institution from Merck, Sharp & Dohme. (Updated November 22, 2024)
Betty J. Dong, PharmD
Professor of Clinical Pharmacy
University of California San Francisco
San Francisco, California
Dr Dong reported no relevant financial relationships with ineligible companies. (Updated March 21, 2025)
Steven C. Johnson, MD
Professor of Medicine
University of Colorado School of Medicine
Aurora, Colorado
Dr Johnson has no relevant financial relationships with ineligible companies to disclose. (Updated November 22, 2024)
Carrie Down Johnston, MD
Assistant Professor of Medicine
Weill Cornell Medicine
New York, New York
Dr Johnston reported consultant or advisor fees from Theratechnologies, Inc. (Updated January 13, 2025)
Harry W. Lampiris, MD
Professor of Clinical Medicine
University of California San Francisco
San Francisco, California
Dr Lampiris has no relevant financial relationships with ineligible companies to disclose. (Updated November 22, 2024)
David L. Wyles, MD
Chief of the Division of Infectious Diseases
Denver Health Medical Center
Denver, Colorado
Dr Wyles reported no relevant financial relationships with ineligible companies. (Updated November 18, 2024)
Planner
Donna M. Jacobsen
Executive Director/President
International Antiviral Society–USA
San Francisco, California
Ms Jacobsen reported no relevant financial relationships with ineligible companies. (Updated March 21, 2025)